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Featured Application: The review aims to provide guidance on the definitions and regulation of
products containing botanical ingredients, which are at present quite complex.
Abstract: In recent decades, the interest in products containing botanicals and claiming “functional”
properties has increased exponentially. Functional foods, novel foods and food supplements have
a special impact on the consumers, who show significant expectation for their well-being. Food
supplements with botanical ingredients are the food area that has witnessed the greatest development,
in terms of the number of available products, budget, and consumer acceptability. This review refers
to and discusses some open points, such as: (1) the definitions and regulation of products containing
botanicals; (2) the difficulty in obtaining nutritional and functional claims (botanical ingredients
obtaining claims in the EU are listed and summarized); (3) the safety aspects of these products; and (4)
the poor harmonization between international legislations. The availability of these “new” products
can positively influence the well-being of the population, but it is essential to provide the consumers
with the necessary recommendations to guide them in their purchase and use.
Keywords: botanicals; food supplements; nutritional claims; functional food
1. Introduction
The sentence “Let thy food be thy medicine and medicine be thy food”, commonly attributed
to Hippocrates (400 BC), indicates the importance that nutrition has always had in the concept of
health and prevention of disease. This relationship has obviously undergone changes and historical
recurrences with an evolution parallel to that of human civilization with its variable habits in social
behavior and diet. More than 2500 years after Hippocrates’ claim, the concept of diet has evolved
to include aspects based on research in the field of nutrition and on knowledge relating to active
molecules contained in foods with potential benefit to human health.
The vegetables entered massively in the diet of humans with the Agricultural Revolution that
occurred about 12,000 years ago. Cereals, only rarely consumed in the Paleolithic era, have become
the basis of human nutrition with milk derivatives [1]. However, considering the use of plants for
their healing properties, archaeological excavations place their use up to 60,000 years ago. These were
plants not commonly consumed as food: poppy (opium), ephedra and cannabis.
The possible placement of the plants among food and products with therapeutic properties is
therefore ancient history and reappears, with its contradictions, in the current legislation, as described
below. The aim of this review was the clarification and relative discussion of the most critical aspects
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regarding products containing botanicals, in order to promote the correct use of plant food supplements
among consumers.
2. Definitions and Regulation
There is no internationally shared definition of the term “botanical”. However, it is possible to cite
what was defined by European Food Safety Authority (EFSA) in its guidelines published in 2009 [2].
The term botanical includes whole, fragmented or cut plants, plant parts, fungi and lichens. The term
botanical preparations include all preparations obtained from botanicals by various processes, such as
pressing, squeezing, extraction, fractionation, distillation, concentration, drying up and fermentation.
A similar definition is reported by a group of food and beverage producers: “botanicals are fresh or dried
plants, plant parts or plants’ isolated or collective chemical components, extracted in water, ethanol,
or other organic solvents, plus essential oils, oleoresins, and other extractives used for flavoring,
fragrance, functional health benefits, medicine, or other uses” [3].
Based on the definitions listed above, it is clear that botanicals include numerous possible
ingredients with extremely variable composition and characteristics. First of all, the presence and
concentration of active molecules can vary greatly, with possible effects on the beneficial effect expected
on the consumers’ health.
Hundreds of plants are ingredients commonly used in the food industry as such or derivatives,
or food additives (flavorings, colorings, preservatives, etc.), and botanicals can be included in different
types of products regulated by the food law as illustrated in Figure 1.
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2.1. Fruits and Vegetables
Fruits and vegetables have been included in the diet of humans since ancient times; they can
be consumed as such or as household or industrial derivatives (jams, juice, purée, etc.). Fruits and
vegetables are included in the EC Regulation N. 178/2002, which defines any unprocessed or processed
substances or product designed for human consumption [4]. Generally speaking, consumers prefer
products from the geographical area of belonging, but with the increasing globalization it is possible to
expand the choice to imported products.
2.2. Enriched or Functional F od
Although there is no international agreement, according to the consensus document on “Scientific
Concepts of Functional Foods in Europe” of the European Commission Concerted Action on Functional
Food Science in Europe (FUFOSE), functional food is usually considered a product to which one or
more ingredients have been added ( r more rarely subtracted) with a positive consequence on the
functionality of human organs or systems [5]. It is, therefore, a food that has not only the function of
providing calories and utrients but intends to carry out a favorable action on the consumer’s health.
This effect must be reached with the q antity of food normally consumed, it must be in “traditional”
form (and ot i pharmaceutical form) and must guarantee the safety of the subjects taking the
product, even if they present common pathologies. As an example, the prebiotic ingredients are
frequently added to food; they are soluble fibers capable to pro ote the growth of the positive intestinal
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microbiota; among others, the most important fibers in this field are inulin and fructo-oligosaccharides
(from chicory or Jerusalem artichoke). Further details will be reported in Section 4.1.2.
2.3. Novel Food and Traditional Food from Third Countries
At the European level the regulation of new food, or novel food, was amended in 2015
(EU Regulation 2015/2283). Compared to the previous regulations, the definition of this products was
maintained: “novel food means any food that was not used for human consumption to a significant
degree within the Union before 15 May 1997”. Some of the categories listed in novel food include
botanicals: (1) food consisting of, isolated from or produced from microorganisms, fungi or algae;
(2) food consisting of, isolated from or produced from plants or their parts. Novel food category also
includes products obtained with new technologies. Before marketing them, appropriate documentation
must be provided in order to demonstrate their safety. Examples of novel food include: new sources of
vitamin K (menaquinone) or some extracts from existing food (Antarctic krill oil rich in phospholipids
from Euphausia superba) [6].
The aforementioned regulation has introduced a new authorization procedure for “traditional
foods deriving from Third Countries”, where a food with proven tradition of safe use in a third country
for at least 25 years is included. Compared to the novel food procedure, this new category must present
less documentation for their approval. Examples of foods belonging to this category are the dried
aerial parts from Hoodia parviflora N.E.Br. (hoodia) and seeds from Salvia hispanica L. (chia) [6].
2.4. Food/Dietary Supplements
Botanicals are widely used in the formulation of food (or dietary in US) supplements, that can be
defined as “products intended to supplement the common diet and which constitute a concentrated
source of nutrients, such as vitamins and minerals, or other substances having a nutritional or
physiological effect, in particular, but not exclusively, amino acids, essential fatty acids, fibers and
extracts of vegetable origin, both single- and multi-compound, in pre-dosed forms” [7]. The role of
food supplements is limited to correcting nutritional deficiencies, maintaining the recommended intake
of some essential nutrients and supporting specific nutritional needs such as pregnancy, breastfeeding
and menopause. They must not show therapeutic activity or significantly modify the physiological
functions [8]. Among the most frequently botanical ingredients used in food supplements, there are
Ginkgo biloba L. (ginkgo), Oenothera biennis L. (evening primrose), Cynara scolymus L. (artichoke) and
Panax ginseng C.A. Meyer (ginseng) [9].
2.5. Other Categories
Botanicals can be regulated by drug law. In fact, their use can enter into conventional medicine, or,
as in some European countries (e.g., Germany), in “Traditional Herbal Medicinal Products (THMPs)”.
THMPs must guarantee their safety in the expected conditions of use and their biological activity/efficacy
must be plausible on the basis of a chronic use and of available experience [10].
Botanicals can also be ingredients of products belonging to the category of medical devices; among
others: (1) ophthalmic solutions containing chamomile (Matricaria recutita L.), calendula (Calendula
officinalis L.), cornflower (Centaurea cyanus L.), etc.; (2) some liquids used in contact lens care, which
include arabinogalactans and plant extracts; (3) some solutions used for oral hygiene containing mainly
chamomile, aloe (Aloe vera (L.) Burm.f.) and marshmallow (Althaea officinalis L.). Since this chapter
is about food, only examples of the use of botanicals in functional foods and food supplements will
be described.
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3. Claims
One of the most interesting aspects associated with functional food and food supplements is the
possibility to boast on the label their health properties, the so-called “claims”.
The European Commission allows health claims when they can be supported by the scientific
literature and if they can be understood by consumers. In the EU, the European Food Safety Authority
(EFSA) is in charge of evaluating the scientific evidence [11] and provides the guidelines, which
describes in detail the studies required for the approval of nutritional/physiological claims [2,12].
There are two types of health sentences, those related to art. 13, and those relating to art. 14 of the
European Regulation 1924/2006. Article 13 claims refer to: (1) growth, development and functions
of the body; (2) psychological and behavioral functions; (3) slimming or weight control. Article 14
claims are associated with: (1) a reduction of risk factors in the development of diseases; (2) support of
normal children’s development and health. Table 1 lists the most important health claims allowed for
vegetable/botanical ingredients in the EU [13].
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Table 1. List of main claims allowed in the EU for plant (botanical) ingredients contained in, or added to, functional food or food supplements [13].
Claim Type Botanical Ingredients Claim Condition of Use of the Claim Restrictions of Use
Art.13(1) Arabinoxylan produced fromwheat endosperm
Consumption of arabinoxylan as part of a meal
contributes to a reduction of the blood glucose rise
after that meal
Food must contain at least 8 g of arabinoxylan-rich fibre/100 g of bioavailable
carbohydrate. The consumer should be informed that the ingredient must be part
of meal.
Art.13(1) Barley grain fibre Barley grain fibre contributes to an increase infaecal bulk
Refer to products included in the claim “high fibre” as listed in the Annex to
Regulation (EC) No 1924/2006.
Art.13(1)
Beta-glucans from oats, oat
bran, barley, barley bran, or
from mixtures of these sources
Beta-glucans contribute to the maintenance of
normal blood cholesterol levels
Food must contain at least 1 g of beta-glucans per quantified portion. Consumers
must be informed that the healthy effect is obtained with a daily intake of 3 g of
beta-glucans.
Art.13(1) Beta-glucans from oats andbarley
Consumption of beta-glucans from oats or barley
as part of a meal contributes to the reduction of
the blood glucose rise after that meal
Food must contain at least 4 g of beta-glucans/30 g of bioavailable carbohydrates.
The ingredient must be part of meal.
Art.13(5) Cocoa flavanols
Cocoa flavanols help maintain the elasticity of
blood vessels, which contributes to normal
blood flow
The positive effect is due to a daily intake of 200 mg of cocoa flavanols having a
degree of polymerization 1-10. Products included: cocoa beverages (with cocoa
powder) or dark chocolate.
Art.13(1) Dried plums of ’prune’cultivars (Prunus domestica L.)
Dried plums/prunes contribute to normal
bowel function The “active” daily intake is 100 g of dried plums (prunes).
Art.13(1) Glucomannan (konjac mannan) Glucomannan contributes to the maintenance ofnormal blood cholesterol levels
Consumer must be informed that the healthy effect is associated with the intake of
three doses of 1 g each, together with 1-2 glasses of water, before meals and
during an energy-restricted diet. Recommendation about an adequate fluid intake
to ensure ingredient reaches the stomach must be added.Art.13(1) Glucomannan (konjac mannan)
Glucomannan in the context of an energy
restricted diet contributes to weight loss
Art.13(1) Guar Gum Guar gum contributes to the maintenance ofnormal blood cholesterol levels
Claim is allowed for foods containing 10 g of guar gum/daily dose recommending
an adequate fluid intake to ensure ingredient reaches the stomach.
Art.13(1) Hydroxypropylmethylcellulose (HPMC)
Consumption of Hydroxypropyl methylcellulose
with a meal contributes to a reduction in the blood
glucose rise after that meal
Claim is allowed for foods containing 4 g of HPMC/per portion during meal.
Recommendation about an adequate fluid intake to ensure ingredient reaches the
stomach must be added.
Art.13(1) Hydroxypropylmethylcellulose (HPMC)
Hydroxypropyl methylcellulose contributes to the
maintenance of normal blood cholesterol levels
Claim is allowed for foods providing 5 g of HPMC/day. Recommendation about
an adequate fluid intake to ensure ingredient reaches the stomach must be added.
Art.13(1) Monascus purpureus(red yeast rice)
Monacolin K from red yeast rice contributes to the
maintenance of normal blood cholesterol levels Claim is allowed for foods providing 10 mg of monacolin K/day.
Art.13(5) Native chicory inulin Chicory inulin contributes to normal bowelfunction by increasing stool frequency
Claim is allowed for foods providing at least 12 g of inulin/day. It must contain
non-fractionated mixture of monosaccharide (<10%), disaccharide, inulin-type
fructans and inulin, with a mean degree of polymerization > or = 9.
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Table 1. Cont.
Claim Type Botanical Ingredients Claim Condition of Use of the Claim Restrictions of Use
Art.13(1) Oat grain fibre Oat grain fibre contributes to an increase infaecal bulk
Refer to products included in the claim “high fibre” as listed in the Annex to
Regulation (EC) No 1924/2006.
Art.13(1) Olive oil polyphenols Olive oil polyphenols contribute to the protectionof blood lipids from oxidative stress
Claim is allowed for olive oils providing at least 5 mg of hydroxytyrosol and its
derivatives in the daily dose, corresponding to 20 g.
Art.13(1) Pectins
Consumption of pectins with a meal contributes to
the reduction of the blood glucose rise after
that meal
Claim is allowed for foods providing 10 g of pectins/portion during meal.
Recommendation about an adequate fluid intake to ensure ingredient reaches the
stomach must be added.
Art.13(1) Pectins Pectins contribute to the maintenance of normalblood cholesterol levels
The claim can be used only when the product provides 6 g of pectins/daily dose
Recommendation about an adequate fluid intake to ensure ingredient reaches the
stomach must be added.
Art.13(1) Plant sterols and plant stanols Plant sterols/stanols contribute to the maintenanceof normal blood cholesterol levels
Claim is allowed for foods providing at least 0.8 g of plant sterols/stanols with the
daily portion.
Art.13(1) Rye fibre Rye fibre contributes to normal bowel function Refer to products included in the claim “high fibre” as listed in the Annex toRegulation (EC) No 1924/2006.
Art.13(5) Sugar beet fibre Sugar beet fibre contributes to increase faecal bulk Refer to products included in the claim “high fibre” as listed in the Annex toRegulation (EC) No 1924/2006.
Art.13(1) Walnuts Walnuts contribute to the improvement of theelasticity of blood vessels Claim is allowed only for food providing with the daily portion 30 g of walnuts.
Art.13(5) Water-soluble tomatoconcentrate (WSTC) I and II
Water-soluble tomato concentrate (WSTC) I and II
helps maintain normal platelet aggregation, which
contributes to healthy blood flow
Consumer must be informed that healthy effect is obtained with a daily dose of
3 g of WSTC I or 150 mg of WSTYC II in: (1) up to 250 mL of liquid products or (2)
food supplements. Liquid products include fruit juices, flavoured drinks or
yogurt drinks; food supplements require a glass of liquid.
Art.13(1) Wheat bran fibre Wheat bran fibre contributes to an acceleration ofintestinal transit
Refer to products included in the claim “high fibre” as listed in the Annex to
Regulation (EC) No 1924/2006. Claim is allowed only for food providing a daily
intake of at least 10 g of bran fibre.
Art.13(1) Wheat bran fibre Wheat bran fibre contributes to an increase infaecal bulk
Refer to products included in the claim “high fibre” as listed in the Annex to
Regulation (EC) No 1924/2006.
Art.14(1)(a) Barley beta-glucans
Barley beta-glucans has been shown to
lower/reduce blood cholesterol. High cholesterol
is a risk factor in the development of coronary
heart disease.
Claim is allowed only for foods providing 3 g of beta-glucan/daily portion.
Art.14(1)(a) Oat beta-glucan
Oat beta-glucan has been shown to lower/reduce
blood cholesterol. High cholesterol is a risk factor
in the development of coronary heart disease
Claim is allowed only for foods providing 3 g of beta-glucan/daily portion.
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Table 1. Cont.
Claim Type Botanical Ingredients Claim Condition of Use of the Claim Restrictions of Use
Art.14(1)(a) Plant sterols/Plant stanol esters
Plant sterols and plant stanol esters have been
shown to lower/reduce blood cholesterol. High
cholesterol is a risk factor in the development of
coronary heart disease.
Claim is allowed only for foods providing a daily intake of 1,5-3 g plant
sterols/stanols. Food categories included: yellow fat spreads, dairy products,
mayonnaise and salad dressings. Reduction of blood cholesterol is estimated:
7–10% with a daily intake of 1.5–2.4 g or 10–12.5% with 2,5-3 g plant
sterols/stanols. The effect appears after 2 to 3 weeks.Art.14(1)(a)
Plant sterols: Sterols extracted
from plants, free or esterified
with food grade fatty acids.
Plant sterols have been shown to lower/reduce
blood cholesterol. High cholesterol is a risk factor
in the development of coronary heart disease.
Art.14(1)(a) Plant stanol esters
Plant stanol esters have been shown to
lower/reduce blood cholesterol. High cholesterol
is a risk factor in the development of coronary
heart disease.
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4. Botanicals in Functional Foods
Some botanical derivatives have been successfully included in functional food for their healthy
properties. Among others, soluble and insoluble fibers, beta glucans and phytosterols/phytostanols
deserve a more in-depth description.
4.1. Soluble and Insoluble Fibers
The beneficial properties of dietary fiber intake have been known for a long time and have been
publicized since the 1920s. Over the years, the importance of fiber for human health has been fluctuating
to be re-evaluated in the second half of the 20th century [14]. With the progress of knowledge, dietary
fiber has been classified in various ways; the first subdivision concerns the difference between fiber,
which are soluble or insoluble in aqueous medium. In addition to the obvious difference in “chemical”
behavior, the solubility (or less) of the fiber in water greatly conditions the activity on humans’ health.
Insoluble fiber acts mainly on the intestinal transit, while the soluble fibers mediate beneficial properties
based on different biological mechanisms.
4.1.1. Insoluble Fiber
Insoluble fiber includes mainly cellulose, hemicellulose and lignin, and it is characterized by
its “inertia” at the level of human organism. In other words, it does not undergo any metabolic
modification during the transit in the gastro-intestinal tract. Products containing insoluble fiber from
different plant sources can use the health claim “the fiber contributes: (1) to normal bowel function;
or (2) to increase faecal bulk; or (3) to an acceleration of intestinal transit” (see barley, oat, rye, sugar
beet, and wheat fiber in Table 1). Insoluble fiber increases fecal bulk, that leads to a speeding of
intestinal transit with the consequent beneficial effects (elimination of waste containing toxic molecules,
less contact of fecal waste with the intestinal mucosa, etc.). These effects have been recognized as
protective factors versus some cancers including the colon cancer.
4.1.2. Prebiotic Fibers
The prebiotic fibers fall into the category of soluble fibers. The definition of the term “prebiotic”
has undergone a certain number of changes since the 1990s, a period in which they were identified as
beneficial ingredients of the human diet. In agreement with the International Scientific Association for
Prebiotics and Probiotics, a prebiotic fiber is “a substrate, that is selectively used by host microorganisms
conferring a health benefit” [15]. Similarly, the Food and Agriculture Organization of the United
Nations (FAO) published the following definition in 2008: “a nonviable food component that confers a
health benefit on the host associated with modulation of the microbiota” [16].
In recent decades, the awareness of the critical role played by the intestinal microbiota on human
health has progressively grown. Studies to support this knowledge have stimulated the formulation of
food products capable to contribute to the modulation of microbiota towards positive bacterial strains
(mainly lactic bacteria) at the expense of pathogenic ones. These foods, mostly milk-based, contain
particular strains of live bacteria (probiotics) or soluble fibers capable of promoting their growth.
In functional foods, the most commonly used prebiotic fibers are: inulin, fructo-oligosaccharides (FOS)
and galacto-oligosaccharides (GOS); the latter are mostly included in products for infants. Inulin is a
linear polymer of 2-60 fructose molecules linked by β-(2-1)-bonds.
The nature of chemical bonds prevents inulin from the usual digestion of caloric sugars. FOS are
similar to inulin for chemical bonds, but the number of units ranges between 2 and 10 [17]. Inulin and
FOS are storage carbohydrates contained in several plants; the most important sources are chicory,
sugar beet, leeks, asparagus, and Jerusalem artichokes. Inulin and FOS reach the colon undigested
where they are fermented by the “positive” microbiota. A health claim for “native chicory inulin” is
allowed in EU; it states that “chicory inulin contributes to normal bowel function by increasing stool
frequency”. This claim must be associated with those products, providing at least a daily intake of 12 g
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of inulin, as a non-fractionated mixture of monosaccharides (<10%), disaccharide, inulin-type fructans
and inulin, with an average of polymerization > 9 (see Table 1).
Although from animal origin, galacto-oligosaccharides (GOS) are considered here to describe the
possible healthy effect due to prebiotic fiber. GOS are oligosaccharides containing 2-10 molecules of
galactose and one molecule of glucose. The purity and degree of polymerization largely influence
the prebiotic properties of these oligosaccharides, as shown in clinical studies [18,19]. GOS are
widely used in lactating formulas to improve the microbiota colonization and modulate the intestinal
disorders such as colic. The effects of GOS added to infant formulas were evaluated in a randomized,
double-blind, controlled, parallel-group clinical trial including healthy term infants [20]. Three groups
were considered: breastfed, formula-fed, and GOS-supplemented formula-fed infants. The effects of
supplemented formula were assessed considering four bacterial targets: Bifidobacterium, Lactobacillus,
Clostridium, and Escherichia coli. The effect of the prebiotic-supplemented formula was very close to that
of breast-feeding in stimulating Bifidobacterium and Lactobacillus growth and in inhibiting Clostridium
growth. The whole result was a significantly lower incidence of colic [20].
4.1.3. Beta-Glucans
Beta-glucans are soluble fibers contained in cereals, such as barley, oat, rye, wheat and some
mushrooms [21]. They are linear polymers of glucose linked by β-(1-4) and β-(1-3) bounds. Two claims
for beta-glucans received positive opinion by EFSA and were included in the list of wordings allowed
in the EU (Table 1) [22].
The first claim is “consumption of beta-glucans from oats or barley as part of a meal contributes
to the reduction of the blood glucose rise after that meal” (Table 1). In fact, beta-glucans modulate the
post-prandial glycemic response by increasing the meal bolus viscosity, with a consequent delayed
absorption of nutrients (including glucose) in the small intestine [23].
On the basis of intervention studies performed in healthy subjects, EFSA concluded that quantities
of about 4 g of beta-glucans/30 g of available carbohydrates are capable to decrease the post-prandial
glycemic response without modifying the insulin release [22]. The claim must be associated with the
recommendation to use beta glucans during meals.
The EFSA received from the European Commission a second request for an opinion regarding the
claim associating beta-glucans with the positive modulation of normal blood cholesterol levels [24].
On the basis of a certain number of randomized-controlled trials in adults with normal or mildly
increased cholesterolemia, the EFSA Panel formulated the following wording “regular consumption
of beta-glucans contributes to the maintenance of normal blood cholesterol levels”. The beneficial
effect is linked to a daily consumption of 3 g of beta-glucans in one or more servings. The proposed
mechanism of action is based on the fact that dietary beta-glucan forms, in the small intestine, a viscous
mixture that reduces the intestinal absorption of dietary cholesterol and the re-uptake of bile acids.
As a consequence, new bile acids are synthetized from circulating cholesterol [25].
4.2. Phytosterols/Phytostanols
Phytosterols and phytostanols are compounds of plant origin, which are commonly part of the
human diet. Phytosterols can be transformed in phytostanols by hydrogenation and both class of
molecules can be esterified with fatty acids from vegetable origin to the corresponding esters [26,27].
Phytosterols and phytostanols are structurally similar to cholesterol, apart from their side chain.
The most common phytosterols and phytostanols are sitosterol, sitostanol, campesterol, campestanol,
stigmasterol and brassicasterol [26].
In the EU, the use of phytosterols, phytostanols and their esters in foods refers to the Regulation
(EC) No. 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel
foods/novel food ingredients.
These molecules reduce the intestinal absorption of cholesterol and, as a consequence, cause
a decrease in blood cholesterol levels. For this property, phytosterols and phytostanols, in free or
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esterified form, can be added to foods for their properties to maintain normal (claim under Art. 13) or
reduce blood cholesterol levels (claim under Art. 14). The first wording is allowed for food providing
0.8 g of plant sterols/stanols with the daily dose and the second for daily doses ranging from 1.5 to 3 g.
Doses of 1.5–2.4 g/day are associated with a cholesterol level reduction of 7–10%, while 2.4–3 g/day can
produce a decrease of 10–12.5% [28].
5. Botanicals in Food Supplements
The category of food/dietary supplements is that in which the presence of ingredients from plant
origin is more frequent (botanicals). Food supplements containing plants or derivatives have found an
increasing diffusion and acceptance by the consumers, which consider the word “natural” synonymous
with “non-chemical” and for association with safe. This belief explains the success of these products
and therefore their consistent market presence.
The plants contained in food supplements are many and most of them derive from the tradition
of use, that is the preparation of infusions or decoctions. The same plants have been then used by the
industries to prepare extracts, in order to enrich the products in active molecules and enhance the
expected positive properties. Supplements may contain a single plant ingredient or a mixture of them.
It is clear that the greater the number of botanicals present in the finished product, the greater the
problems in the correct use by the consumer and in the quality control especially when the product is
already on sale.
Another critical aspect derives from the fact that there is no harmonization at the international
level (even in Europe) as regards the lists of plants allowed in food supplements. Many countries of
the European Union, but also of other continents, have published positive and/or negative lists of
botanical ingredients, which are allowed or prohibited in food/dietary supplements. Unfortunately,
there is few correlations between them.
The inconsistent situation of the European market of products with botanical ingredients (presence
both in products regulated by food or drug laws, see Section 2) leads to several consequences, including
the difficulty in discriminating “healthy” or “therapeutic” information for the same plant used in
different product classes. As the researchers well know, the dose makes the difference, but discriminating
the dose with physiological effects from the one that is suitable for clinical applications is a complex
objective even for plants of more ancient tradition. These difficulties were reflected in the very small
number of claims approved by EFSA in the field of botanicals.
To boast a nutritional or health claim as a guide for the consumer, it is necessary to refer to
the European Regulation n. 1924/2006, according to which: "Scientific substantiation should be the
main aspect to be taken into account for the use of nutrition and health claims and the food business
operators using claims should justify them”. To obtain authorization to associate a nutrition/health
claim with a botanical in EU, the manufacturer must submit a dossier to EFSA, which evaluates the
scientific evidence of the studies provided and publishes the relative opinion. The guidelines provided
by EFSA [2,8] describe in detail the studies required for the approval of nutritional/physiological claims.
The guidelines published by EFSA, although extremely well-articulated, have nevertheless led to
immediate difficulties in the creation of a dossier that could meet all the listed requirements. Among
the most critical and important aspects:
(a) speaking of dietary supplements, food industries cannot claim any therapeutic effect, but only
physiological ones; as a consequence, apart from few exceptions, it is very difficult to prove a healthy
activity that aims to maintain homeostasis or reducing disease risk factors in the long term;
(b) to obtain statistical significance, it is necessary to recruit a very large “healthy” population
that is willing to take a certain product for very long periods. All this is economically unsustainable,
and the results could still be affected by the dietary habits (and not only) of the subjects considered;
(c) it seems unreasonable that the tradition of use has been accepted for traditional medicine drugs
and not for food supplements.
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Considering the list of claims listed in Table 1, only one case can be clearly associated with
food supplements: Monascus purpureus (red yeast rice); in the remaining cases, claims are related to
ingredients generally used in all foods.
Red Yeast Rice (RYR) is a rice fermented by the red yeast Monascus purpureus, which contain a
certain number of active polyketides named monacolins, that are secondary metabolites deriving from
the fermentation process [29]. The most abundant active molecule is monacolin K.
RYR obtained the approval of the claim: “Monacolin K from red yeast rice contributes to the
maintenance of normal blood cholesterol levels” [30]. This wording was supported by two randomized
controlled studies, where RYR preparations providing 10 mg of monacolin K (with the daily dose)
were responsible of a reduction of blood Low-Density Lipoprotein- cholesterol (LDL-cholesterol) level
in subjects suffering from hypercholesterolemia. EFSA considered also the fact that the effect of pure
monacolin K (chemically identical to the drug lovastatin) on blood LDL-cholesterol concentration was
well known and based on the inhibition of HMG-CoA (3-hydroxy-3-methyl-glutaryl -Coenzyme A)
reductase [31].
6. Safety Aspects
This chapter deals with food, the safety of which should be able to be taken for granted. Actually,
when botanicals are food supplement ingredients, some distinction has to be made. Compared to
common or functional food, food supplements containing botanicals have no or little role from the
nutritional point of view, as these do not contribute significantly to the intake of calories and nutrients.
In fact, normally these products do not contain caloric nutrients (sugars, fats and proteins) and
the presence of vitamins and minerals (not mandatory) covers, with a few exceptions, very limited
percentages of the recommended daily dose. On the other hands, food supplements with botanicals
are frequently promoted for their possible healthy properties, leading the consumer to prolonged use
over time. Furthermore, as mentioned above, the growing popularity among consumers of “natural
products” has led to an increasing number of producers and thousands of food supplements on
the international market, without certainties relating their composition, activity and safety. While
biological activity may be at least partly based on the “tradition of use”, the risk/benefit assessment
still remains orphaned of sufficiently reliable scientific data.
Botanicals, especially if in their extract form, can have biological effects which, in relation to
the dose and quality of the ingredient, can be functional, therapeutic and also toxic [32]. Different
factors could be involved in the incidence of adverse effects such as the quality of the raw botanical
material, the presence of environmental contaminants, the specific technological process applied
(extraction and concentration), misidentifications of the plant ingredients, adulterations, counterfeits.
The phytochemical fingerprint of a botanical can vary significantly, when the biological variability or
the different processes applied are considered. Different factors (extractant solvent, the temperature and
time, the time from harvesting, etc.) can modulate the quality of botanical ingredients, with consequent
changes in the relative abundance of active molecules present in the final product. Consumer’s age
and gender, unsuitable use of botanical food supplements, genetic factors and specific pathological or
physiological conditions are further possible sources of unexpected adverse reactions.
Confirming the particularity of the supplements with respect to usual food, there are cases in
which limits on the content of molecules naturally present in botanicals are regulated by national and
international directives. The established values must also be indicated on the label, such as in the case
of bitter orange (Citrus aurantium L.) for which it is necessary to declare the content of synephrine and
other active amines with the daily dose (Figure 2). Limits are established for molecules that can lead to
unwanted side effects at high levels and therefore for which safe daily doses for consumers need to be
“standardized”.
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6.1. Adverse Events
Even in the case of adverse events, supplements containing botanicals show specific characteristics.
Excluding the accidental presence of toxic xenobiotics, the adverse events associated with common foods
are mostly due to allergies and intolerances, which concern restricted groups of at-risk populations.
On the contrary, in the case of supplements with botanicals, the consumer must be informed that
adverse events can occur. Moreover, pregnant, lactating women and children should avoid food
supplements or strictly follow the doctor’s/pediatrician’s indications.
Since botanicals are “natural”, the average consumer considers them safe and rarely communicates
their use to doctors in the case of short- or long-term therapy. This point is probably the most
important factor leading to unexpected adverse effects. Botanicals could modify the efficacy of other
molecules (pharmaceutical drugs or other dietetic compounds) reducing or increasing their plasmatic
concentration. To give an example of the possible adverse events to supplements containing botanicals,
the case of RYR is described here.
6.2. The Case of RYR
As described previously (see Section 5), in 2011 RYR received a positive opinion for the claim
supporting the reduction of LDL-cholesterol plasma level, if the daily intake of monacolin K was 10 mg.
In 2018, the EFSA was asked a second time relation to RYR, with the request being to eva uate
the safety of the monacolins contained in it and to provide advice on the daily dose f monacolins
that does not give rise to concern for har ful effec s [33]. Since the lactonic form of m nacolin K
as th same che ic l structure of lovastatin (a pharmaceutical drug), t EFSA, aft r consulting the
scientific material provided, oncluded that the intake of 10 mg of monacolin K with a food supplement
would l ad to the in ake of a therapeutic dose. Moreov r, the evaluation of the data prese ted showed
that several adverse e ents were reported following the c nsumption of RYR. These adverse events
invo ved musculosk letal system (th most severe clinical event ass ciated was rhabd myolysis) nd
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liver. The clinical symptoms appeared after consumption of RYR, with an intake of 3–10 mg/day of
monacolin K.
Two problems have therefore been highlighted for RYR:
1. the dose of monacolin K required to boast the claim about the LDL-cholesterol reduction
corresponded to the lower therapeutic dose of the drug lovastatin, chemically identical to the
lactonic form of monacolin K. This fact is not acceptable due to the legal definition of a dietary
supplement, which must not show pharmacological activity.
2. the EFSA “was unable to identify a dietary intake of monacolins from RYR that does not give
rise to concerns about harmful effects to health, for the general population, and as appropriate,
for vulnerable subgroups of the population”. This fact makes uncertain the marketing of RYR as
food supplement, products that do not require medical supervision.
7. Conclusions
Since the last century, a progressive lengthening of the average life of the population has been
observed; this social phenomenon is in itself a positive fact, but inevitably entails an increase in the
occurrence of chronic-generative diseases more frequent in elderly: cardiovascular diseases, tumors,
dementias, etc. At the same time, new data on the role of nutrition in human health has stimulated
important international researches and industrial activities:
1. the tables of nutritional requirements (RDA) have been prepared which, with some differences,
indicate to consumers all over the world the quantity of calories and nutrients necessary to
maintain health;
2. the possible protective role of some components present in foods (antioxidants are the most
popular) against the chronic-degenerative diseases described above has been highlighted.
These premises explain the great interest of the food industry for products that present, in addition
to nutritional ingredients (proteins, carbohydrates and fats), new “functional” properties, which
have special impact on the consumer. In this area, particular interest has been paid to ingredients
of vegetable origin, the botanicals. Most products containing botanicals are regulated by food law:
fruits and vegetables, functional foods, novel foods, traditional foods from third countries, and food
supplements. Some botanical ingredients have received positive opinion by EFSA to support their
health claims; fibers, beta glucans and phytosterols/phytostanols are among the most known functional
ingredients. Food supplements with botanical ingredients are the sector that has witnessed the greatest
development, in terms of both the number of products on the market and consumer acceptability.
The availability of these “new” functional products can positively influence the well-being of the
population, but it is essential to provide the consumer with the necessary information to guide him in
the purchase and use of food supplements.
The difficulties in demonstrating scientifically the supposed physiological/healthy properties
of botanicals are the reasons of the limited number of claims approved by EFSA. In addition, safety
aspects should be considered in relation to the high number of products available on the market and
their growing popularity among consumers: among other things, the quality of raw materials, possible
adulterations, presence of active molecules regulated by national/international directives and factors
associated with consumers (age, gender, concomitant diseases/drugs). These factors can contribute to
adverse effects occurring, underlying the need for tools and intervention to promote consumers safety.
In conclusion, this review provides an overview on the actual knowledge about products containing
botanicals aimed to promote consumers’ wellbeing. The main purpose is to provide useful information
to consumers in order to guide their choices. In fact, although much progress has been made in the
field of botanicals, there is still a lack of data, information, and guidelines to ensure the suitable use of
these products.
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